The British Journal of Psychiatry · 2009 · 176 citations · 8 references
MedicinePharmacologyPsychiatryNeurochemistryNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyCannabinoid PharmacologyMonoamine NeurochemistryNeurotransmissionSchizophrenia Spectrum DisordersCannabinoid BiomarkersCannabinoid Receptor PharmacologyEndocannabinoid MetabolismEndocannabinoid SignalingEndocannabinoid SystemHigh-performance Liquid Chromatography-mass SpectrometryLiquid Chromatography-mass SpectrometryLiquid Chromatography-mass Spectrometry Analysis
Anandamide is a bioactive lipid binding to cannabinoid receptors. A homeostatic role for anandamide has been suggested in schizophrenia. We investigated its role in initial prodromal states of psychosis. We measured the levels of anandamide and its structural analog oleoylethanolamide in cerebrospinal fluid and serum of patients in the initial prodromal state (n=27) alongside healthy volunteers (n=81) using high-performance liquid chromatograph/mass spectrometry. Cerebrospinal anandamide levels in patients were significantly elevated. Patients with lower levels showed a higher risk for transiting to psychosis earlier. This anandamidergic up-regulation in the initial prodromal course may suggest a protective role of the endocannabinoid system in early schizophrenia.
8
Elevated endogenous cannabinoids in schizophrenia
F. Markus Leweke, Andrea Giuffrida, U Wurster et al. · Neuroreport · 1999 · 433 citations · Full text
Medicine, Pharmacology, Psychiatry +10